Published: February 3rd, 2022,
Last updated: February 3rd, 2022
China is entering the race to develop a viable antibody therapy against COVID-19. A Shanghai-based research team announced the development of a new type of antibody that is able to neutralize Omicron and future coronavirus variants. This could present a decisive edge against the virus in the race against the pandemic, said lead researcher Huang Jinghe of Shanghai’s Fudan University. According to a report in the South China Morning Post, the new antibody was assembled from components of two different antibodies produced by human immune cells. On their own, both types of antibodies would be useless against Omicron. But the artificially assembled version has had success in fighting the virus.